Post-GWAS Functional Genomics Analysis to Define Pathogenic Mechanisms for Pulmonary Arterial Hypertension
GWAS 后功能基因组学分析确定肺动脉高压的致病机制
基本信息
- 批准号:10524975
- 负责人:
- 金额:$ 16.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffinityAllelesAllelic ImbalanceAnimal ModelArchitectureBasic ScienceBindingBiologyBlood VesselsCRISPR/Cas technologyCell LineClinicalCoupledDNA BindingDNA Sequence AlterationDataDependenceDependovirusDevelopmentDiagnosticDiseaseDisease susceptibilityDown-RegulationEndotheliumEnterochromaffin CellsEnvironmentExperimental Animal ModelFunctional disorderFutureGene ExpressionGenesGeneticGenetic Predisposition to DiseaseGenomic approachGenomicsGenotypeGoalsHaplotypesHumanHypoxiaInterventionKnockout MiceKnowledgeLinkLinkage DisequilibriumLungLung diseasesMediatingMentorsMethodsMolecularMolecular TargetMusMutationNamesPathogenesisPathogenicityPathway interactionsPatientsPersonsPhysiciansPolymersPredispositionProteinsPulmonary HypertensionReportingResearchResearch PersonnelResearch Project GrantsResearch TechnicsResourcesRiskRoleSOX17 geneSamplingScientistSeveritiesSingle Nucleotide PolymorphismStructure of parenchyma of lungTechniquesTechnologyTestingTrainingTranslational ResearchUniversitiesUntranslated RNAValidationWorkbasecareercareer developmentendothelial dysfunctionfamilial hypertensionfunctional genomicsgenetic associationgenome wide association studygenomic locusgenomic platformhuman DNAin vivoinduced pluripotent stem cellinsightknock-downknowledge baselung hypoxiamouse modelnanoparticlenoveloverexpressionpulmonary arterial hypertensionpulmonary artery endothelial cellrisk variantsiRNA deliveryskillsstem cell biologytranscription factorvector
项目摘要
PROJECT SUMMARY
Pulmonary arterial hypertension (PAH) is an enigmatic and morbid disease where insights are emerging
regarding genetic susceptibility to disease. Genome-wide Association Studies (GWAS) have identified single
nucleotide polymorphisms (SNPs) that are associated with PAH risk and severity. Yet, the GWAS-reported SNPs
are only tags of haplotype SNPs in linkage disequilibrium (LD). Thus, the tag SNP may simply be linked to the
true disease-causing functional SNP (fSNP). GWAS also only reveal statistical associations, and it has been
challenging to define the mechanisms underlying the contribution of the PAH-associated fSNPs, which are
mostly located in the non-coding regions, to the pathogenesis of PAH. Using our recently developed post-GWAS
functional genomics platform, I identified a non-coding fSNP rs4738801 in the genomic locus of SOX17 gene, a
known endothelial effector increasingly being studied in PAH pathogenesis. I identified that the transcription
factor FUBP1 binds to the rs4738801 risk allele C in an allele-imbalanced manner, with lower affinity to risk allele
C than non-risk allele G, providing an underlying mechanism how this fSNP regulates the PAH pathogenic gene
SOX17 and contributes to the PAH risk. FUBP1 controls PAH-associated pathophenotypes in pulmonary arterial
endothelial cells (PAECs). Downregulated by the major acquired PAH trigger hypoxia, FUBP1 and its target
gene SOX17 are decreased in lungs and isolated pulmonary ECs from PAH patients and mouse models. A 3.77-
fold enrichment of fSNP rs4738801 risk allele C was found in patients with PAH induced by hypoxia, supporting
a pathogenic mechanism of a hypoxia-sensitive pathway (FUBP1-SOX17) combined with a disease susceptible
genotype (risk allele C) for clinical manifestation of this disease. Based on these data, I hypothesize that the
allele-imbalanced binding of transcription factor FUBP1 to fSNP rs4738801 defines the genomic architecture
contributing to the SOX17-dependent genetic susceptibility of PAH. I further postulate that the downregulation
of FUBP1-SOX17 by hypoxia contributes to the acquired pathogenesis of PAH. To test this hypothesis, I propose
2 specific aims: 1) To define the allele-specific role of fSNP rs4738801 in promoting endothelial dysfunction in
PAH in gene-edited iPSC-ECs and PAH patient lung tissues; and 2) To determine the role of FUBP1 in controlling
SOX17 and PAH in mouse models. Accomplishing these aims will facilitate my enduing career goal of becoming
an independent physician-scientist in PAH functional genomics research. Immediate scientific development
objectives include: 1) To develop expertise in PAH genetics and functional genomics; 2) To develop expertise in
iPSC-EC biology and CRISPR-Cas9 gene-editing techniques; and 3) To develop skills of in vivo gene expression
manipulation and become proficient in the assessment of PAH in animal models. The proposed training plan will
provide me with the opportunity to expand my knowledge base to include advanced research techniques in PAH
pathogenesis. The resources and expertise of my mentors, contributors, and the rich research environment at
the University of Pittsburgh will assure my successful transition to an independent investigator.
项目摘要
肺动脉高压(PAH)是一种神秘的病态疾病,
关于疾病的遗传易感性。全基因组关联研究(GWAS)已经确定了单个
与PAH风险和严重程度相关的核苷酸多态性(SNP)。然而,GWAS报告的SNP
是连锁不平衡(LD)中单倍型SNPs的唯一标签。因此,标签SNP可以简单地连接到标签SNP。
真正致病功能性SNP(fSNP)。GWAS也只揭示了统计学上的关联,
定义PAH相关fSNP的作用机制具有挑战性,
大多位于非编码区,与PAH的发病有关。使用我们最近开发的后GWAS
在功能基因组学平台上,我在SOX 17基因的基因组位点上鉴定了一个非编码fSNP rs 4738801,
已知的内皮效应物在PAH发病机制中的研究越来越多。我发现这份抄本
因子FUBP 1以等位基因不平衡的方式与rs 4738801风险等位基因C结合,对风险等位基因具有较低的亲和力
C比非风险等位基因G,提供了该fSNP如何调节PAH致病基因的潜在机制
SOX 17,并导致PAH风险。FUBP 1控制肺动脉中PAH相关的病理表型
内皮细胞(PAECs)。由主要获得性PAH触发缺氧下调的FUBP 1及其靶点
基因SOX 17在肺和来自PAH患者和小鼠模型的分离的肺EC中减少。A 3.77-
在缺氧诱导的PAH患者中发现fSNP rs 4738801风险等位基因C的倍数富集,支持
缺氧敏感性通路(FUBP 1-SOX 17)的致病机制与易受
基因型(风险等位基因C)的临床表现,这种疾病。根据这些数据,我假设
转录因子FUBP 1与fSNP rs 4738801的等位基因不平衡结合定义了基因组结构
有助于PAH的SOX 17依赖性遗传易感性。我进一步假设下调
缺氧诱导FUBP 1-SOX 17基因表达的改变参与了PAH的获得性发病机制。为了验证这个假设,我建议
2个具体目的:1)确定fSNP rs 4738801在促进内皮功能障碍中的等位基因特异性作用,
基因编辑的iPSC-EC和PAH患者肺组织中的PAH;以及2)确定FUBP 1在控制PAH中的作用。
SOX 17和PAH在小鼠模型中的作用实现这些目标将有助于我实现职业目标,
PAH功能基因组学研究方面的独立医生兼科学家。近期科学发展
目标包括:1)培养PAH遗传学和功能基因组学方面的专业知识; 2)培养以下方面的专业知识:
iPSC-EC生物学和CRISPR-Cas9基因编辑技术;以及3)开发体内基因表达的技能
操作,并成为在动物模型中PAH的评估熟练。拟议的培训计划将
为我提供了扩展知识基础的机会,包括PAH的先进研究技术
发病机制我的导师,贡献者的资源和专业知识,以及丰富的研究环境,
匹兹堡大学将确保我成功转型为独立调查员
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wei Sun其他文献
Wei Sun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wei Sun', 18)}}的其他基金
Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit
用于早期癌症评估的液体活检的竞争前合作:数据管理和协调单位
- 批准号:
10838127 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague
鼠疫耶尔森氏菌外膜囊泡疫苗
- 批准号:
10673295 - 财政年份:2022
- 资助金额:
$ 16.07万 - 项目类别:
Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague
鼠疫耶尔森氏菌外膜囊泡疫苗
- 批准号:
10555332 - 财政年份:2022
- 资助金额:
$ 16.07万 - 项目类别:
Yersinia Outer-Membrane-Vesicle Vaccines Against Pneumonic Plague
鼠疫耶尔森氏菌外膜囊泡疫苗
- 批准号:
10441853 - 财政年份:2022
- 资助金额:
$ 16.07万 - 项目类别:
Post-GWAS Functional Genomics Analysis to Define Pathogenic Mechanisms for Pulmonary Arterial Hypertension
GWAS 后功能基因组学分析确定肺动脉高压的致病机制
- 批准号:
10697364 - 财政年份:2022
- 资助金额:
$ 16.07万 - 项目类别:
Statistical Methods for T Cell Receptor (TCR) Analysis
T 细胞受体 (TCR) 分析的统计方法
- 批准号:
10620574 - 财政年份:2022
- 资助金额:
$ 16.07万 - 项目类别:
Statistical Genetics and Genomics for Epidemiologic Research
流行病学研究的统计遗传学和基因组学
- 批准号:
10426287 - 财政年份:2018
- 资助金额:
$ 16.07万 - 项目类别:
A novel computing framework to automatically process cardiac valve image data and predict treatment outcomes
一种新颖的计算框架,可自动处理心脏瓣膜图像数据并预测治疗结果
- 批准号:
9973167 - 财政年份:2018
- 资助金额:
$ 16.07万 - 项目类别:
Yersinia pseudotuberculosis-based vaccines for plague and yersiniosis
基于假结核耶尔森氏菌的鼠疫和耶尔森氏菌疫苗
- 批准号:
9471106 - 财政年份:2016
- 资助金额:
$ 16.07万 - 项目类别:
Biomechanical study on aortic-mitral coupling in transcatheter aortic valve replacement
经导管主动脉瓣置换术中主动脉-二尖瓣耦合的生物力学研究
- 批准号:
9274379 - 财政年份:2016
- 资助金额:
$ 16.07万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 16.07万 - 项目类别:
Continuing Grant